Antiretroviral therapy regimens containing the HIV protease inhibitor saquinavir
- Autores: Kravchenko A.V.1
-
Afiliações:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Edição: Nº 3 (2015)
- Páginas: 50-54
- Seção: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278263
- ID: 278263
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
The paper gives the results of Russian and international clinical trials of antiretroviral therapy (ART) regimens including the HIV protease inhibitor (PI) ritonavir-enhanced saquinavir (SQV/r). The efficacy and safety of SQV/r 1000/100 mg twice daily have been clearly demonstrated by the results of both randomized trials (Gemini) and by the data obtained in real clinical practice (Rainbow), including those in special patient groups (pregnant women, patients with chronic viral hepatitides). Examination of the pharmacokinetics of SQV/r has indicated that the daily dose of the drug should not be changed in women in the third trimester and in patients with obvious liver fibrosis. The ART regimens containing SQV/r are noted to have a positive impact on lipid metabolic parameters, which can recommend the change of the current effective ART regimen, by replacing the used PI by SQV/r mainly in patients with high (third-to-fourth-degree toxicity) levels of triglycerides and total cholesterol.
Palavras-chave
Texto integral
Sobre autores
Aleksey Kravchenko
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: kravtchenko@hivrussia.net
Moscow
Bibliografia
- Кравченко А.В., Серебровская Л.В., Голохвастова Л.Е., Шипулин Г.А., Богословская Е.В., Горбачева Э.С. Тимазид в сочетании с хивидом и инвиразой в комплексной терапии больных ВИЧ-инфекцией. Эпидемиология и инфекционные болезни 1998; 5: 51-53.
- Кравченко А.В., Ситдыкова Ю.Р., Серебровская Л.В., Богословская Е.В., Иванова Л.А., Покровский В.В. Комбинированная антиретровирусная терапия больных ВИЧ-инфекцией с использованием «усиленных» ингибиторов протеазы ВИЧ. Инфекционные болезни 2003; 1(1): 14-19.
- Walmsely S., Avihingsanon A., Slim J., Ward D.J., Ruxrungtham K., Brunetta J., Bredeek U.F., Jayaweera D., Guittari C.J., Larson P., Schutz M., Raffi F. GEMINI: a noninferiority study of saquinavir/ritonavir versus lopinavir/ ritonavir as initial HIV-1 therapy in adults. J. Acquir. Immune Defic. Syndr. 2009; 50(4): 367-374.
- Knechten H., Stephan C., Mosthaf F.A., Jaeger H., Carganico A., Lutz T., Schewe K., Mayr C., Wolf E., Wellmann E., Tappe A. The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients. Eur. J. Me.d Res. 2011; 16(3): 93-100.
- Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe (Version 7.1; November, 2014). European AIDS Clinical Society. http://www.eacsociety.net
- Покровский В.В., Юрин О.Г., Кравченко А.В., Беляева В.В., Канестри В.Г., Афонина Л.Ю., Ермак Т.Н., Буравцова Е.В., Шахгильдян В.И., Козырина Н.В., Нарсия Р.С., Зимина В.Н., Покровская А.В., Ефремова О.С. Протоколы диспансерного наблюдения и лечения больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2014; 6, приложение. 48 с.
- Brunet C., Reliquet V., Jovelin T., Venisse N., Winer N., Bui E., Le Moal G., Perfezou P., De Saint Martin L., Raffi F. Effectiveness and safety of saquinavir/ritonavir in HIV-infected pregnant women: INEMA cohort. Med. Mal. Infect. 2012; 42(9): 421-428.
- Martinez-Rebollar M., Lonca M., Perez I., Soy D., Brunet M., Martin R., Coll O., Hernandez S., Laguno M., Milinkovic A., Larrousse M., Calvo M., Blanco J.L., Martinez E., Gatell J.M., Mallolas J. Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. Ther. Drug. Monit. 2011; 33(6): 772-777.
- Салминская О.И. Опыт применения Инвиразы в составе трехкомпонентной терапии как препарата выбора при перинатальной профилактике передачи ВИЧ-инфекции в Ульяновской области. Тер. архив 2013; 85(11): 16-20.
- Канестри В.Г., Кравченко А.В., Ганкина Н.Ю. Гепатотоксичность антиреровирусной терапии больных ВИЧ-инфекцией. Эпидемиол. инфекц. болезни. Актуал. вопр. 2015; 1: 31-36.
- Moltó J., Llibre J.M., Ribera E., Míaguez C., del Río J.S., Pedrol E., Vallecillo G., Cedeño S., Valle M., Miranda C., Negredo E., Clotet B. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. J. Antimicrob. Chemother. 2009; 63(5): 992-997.
- Stephan C., Jaeger H., Carganico A., Knecht G., Lutz T., Mayr C., Mosthaf F.A., Koeppe S., Mueller M., Wolf E., Tappe A., Wellmann E., Knechten H. Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients Eur. J. Med. Res. 2010; 15(9): 369-376.
Arquivos suplementares
